KIOM-79 抑制醛糖还原酶活性和糖尿病肥胖 Zucker 大鼠白内障的形成。
KIOM-79 inhibits aldose reductase activity and cataractogenesis in Zucker diabetic fatty rats.
机构信息
Diabetic Complications Research Center, Division of Traditional Korean Medicine Integrated Research, Korea Institute of Oriental Medicine, Daejeon, South Korea.
出版信息
J Pharm Pharmacol. 2011 Oct;63(10):1301-8. doi: 10.1111/j.2042-7158.2011.01341.x. Epub 2011 Aug 16.
OBJECTIVES
KIOM-79, a combination of four plant extracts, has a preventive effect on diabetic nephropathy and retinopathy in diabetic animal models. In this study, we have investigated the inhibitory effects of KIOM-79 on diabetic cataractogenesis.
METHODS
We evaluated aldose reductase activity during cataractogenesis using Zucker diabetic fatty (ZDF) rat, an animal model of type 2 diabetes. ZDF rats were treated orally with KIOM-79 (50 mg/kg body weight) once a day for 13 weeks.
KEY FINDINGS
In vehicle-treated ZDF rats, lens opacity was increased, and lens fibre swelling and membrane rupture were observed. In addition, aldose reductase activity and aldose reductase protein expression in diabetic lens were markedly enhanced. However, the administration of KIOM-79 inhibited the development of diabetic cataract through the inhibition of aldose reductase activity and protein expression in diabetic lenses.
CONCLUSIONS
These observations suggested that KIOM-79 was useful against the treatment of diabetic cataractogenesis.
目的
KIOM-79 是由四种植物提取物组成的混合物，对糖尿病动物模型中的糖尿病肾病和视网膜病变具有预防作用。在本研究中，我们研究了 KIOM-79 对糖尿病性白内障形成的抑制作用。
方法
我们使用 2 型糖尿病动物模型 Zucker 糖尿病肥胖（ZDF）大鼠评估白内障形成过程中的醛糖还原酶活性。ZDF 大鼠每天口服 KIOM-79（50mg/kg 体重），共 13 周。
主要发现
在未治疗的 ZDF 大鼠中，晶状体混浊增加，晶状体纤维肿胀和膜破裂。此外，糖尿病晶状体中的醛糖还原酶活性和醛糖还原酶蛋白表达明显增强。然而，KIOM-79 的给药通过抑制糖尿病晶状体中醛糖还原酶活性和蛋白表达抑制了糖尿病性白内障的发展。
结论
这些观察结果表明，KIOM-79 可有效用于治疗糖尿病性白内障形成。
Zotero 插件